Three parenteral GP IIb/IIIa inhibitors, abciximab, tirofiban, and epfitibatide, are approved for clinical use in North America and Europe. All three drugs have been tested in two different clinical scenarios: (a) given immediately before percutaneous coronary intervention (PCI) to the full ...
Three parenteral GP IIb/IIIa inhibitors, abciximab, tirofiban, and epfitibatide, are approved for clinical use in North America and Europe. All three drugs have been tested in two different clinical scenarios: (a) given immediately before percutaneous coronary intervention (PCI) to the full ...
Gruberg L, Suleiman M, Kapeliovich M, Hammerman H, Grenadier E, Boulus M, et al. Glycoprotein IIb/IIIa inhibitors after full-dose thrombolysis in rescue Angioplasty for acute myocardial infarction: To give or not give? Am J Cardiol. 2002;90(6A):TCT427....
Age, lean body mass and renal function also contribute to pharmacologic heterogeneity, and these factors have been shown to impact the efficacy and safety of glycoprotein IIb/IIIa inhibition (34). Creatinine clearance is especially relevant to the small-molecule inhibitors since their excretion is alm...
Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journal of SerbiaJeлeHKoBи, A.
The involvement of glycoprotein (GP) IIb-IIIa (IIb3-integrin) in the stimulation of secretion from platelet dense and -granules was investigated. Fibrinogen binding with GP IIb-IIIa and platelet aggregation were inhibited by fragments of anti-GP IIb-IIIa monoclonal antibodies (monAB)—Fab fragment...
Objective: To review the clinical trials of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors for unstable angina or non–ST segment elevation myocardial infarction (MI) and to provide a practice guide for the use of these agents in this setting. Methods: Clinical trials relating to GPIIb/IIIa antag...
Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease Dean J. Kereiakes MD& Pascal J. Goldschmidt-Clermont MD Part of the book series:Contemporary Cardiology((CONCARD)) 109Accesses Abstract Adjunctive blockade of platelet glycoprotein (GP) IIb/IIIa during percutaneous coronary intervention ...
Thrombosis Research 90 (1998) 247–258REGULAR ARTICLEGlycoprotein IIb/IIIa Receptor AntagonistsInhibit the Development of Platelet Procoagulant ActivityDonna L. Pedicord, Beth E. Thomas, Shaker A. Mousa and Ira B. DickerThe DuPont Merck Pharmaceutical Company, Experimental Station, Wilmington, Delaware,...
This study in conjunction with other studies of glycoproteinIIb/IIIareceptorinhibitorssuggeststhataclass effect of these agents should not be assumed and suggests that only those agents proven effective for a specific indica- tion should be used in the treatment of patients with acute coronary syndrome...